Efficacy of COVID-19 Vaccine

S. Islam
{"title":"Efficacy of COVID-19 Vaccine","authors":"S. Islam","doi":"10.3329/jopsom.v40i2.61799","DOIUrl":null,"url":null,"abstract":"With the onset of the novel coronavirus, scientists and medical professionals worked tirelessly to develop an effective clinically approved vaccine for the same. Initially what seemed impossible is now a reality and not only have experts manufactured COVID vaccines in such a short span of time, but they have also developed different types and versions of it too. Equitable access to safe and effective vaccines is critical to ending the COVID- 19 pandemic, so it is hugely encouraging to see so many vaccines proving and going into development. WHO is working tirelessly with partners to develop, manufacture and deploy safe and effective vaccines. Safe and effective vaccines are a game-changing tool. Being vaccinated does not mean that we can throw caution to the wind and put ourselves and others at risk, particularly because research is still ongoing into how much vaccines protect not only against disease but also against infection and transmission. But it’s not vaccines that will stop the pandemic, rather it’s vaccination with proper efficacy. Out of more than 100 research articles on COVID-19 and SARS-CoV-2 vaccines 41 articles were included in the present study. As of 1 May 2021, there have been 152 661 445 Covid-19 cases with 3 202 256 deaths globally. This pandemic led to the race to discover a safe and effective vaccine to achieve herd immunity and curtail the damaging effects of Covid-19. This study aims to discuss the most recent WHO-approved Covid-19 vaccine subtypes, their trials, doses and efficacy. As of 16 May 2021, the number of countries that have approved the use of the following vaccines is Pfizer in 85, Moderna in 46, Oxford/AstraZeneca in 101, and Janssen in 41.\nJOPSOM 2021; 40(2):65-72","PeriodicalId":84897,"journal":{"name":"Indian journal of preventive and social medicine","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of preventive and social medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/jopsom.v40i2.61799","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

With the onset of the novel coronavirus, scientists and medical professionals worked tirelessly to develop an effective clinically approved vaccine for the same. Initially what seemed impossible is now a reality and not only have experts manufactured COVID vaccines in such a short span of time, but they have also developed different types and versions of it too. Equitable access to safe and effective vaccines is critical to ending the COVID- 19 pandemic, so it is hugely encouraging to see so many vaccines proving and going into development. WHO is working tirelessly with partners to develop, manufacture and deploy safe and effective vaccines. Safe and effective vaccines are a game-changing tool. Being vaccinated does not mean that we can throw caution to the wind and put ourselves and others at risk, particularly because research is still ongoing into how much vaccines protect not only against disease but also against infection and transmission. But it’s not vaccines that will stop the pandemic, rather it’s vaccination with proper efficacy. Out of more than 100 research articles on COVID-19 and SARS-CoV-2 vaccines 41 articles were included in the present study. As of 1 May 2021, there have been 152 661 445 Covid-19 cases with 3 202 256 deaths globally. This pandemic led to the race to discover a safe and effective vaccine to achieve herd immunity and curtail the damaging effects of Covid-19. This study aims to discuss the most recent WHO-approved Covid-19 vaccine subtypes, their trials, doses and efficacy. As of 16 May 2021, the number of countries that have approved the use of the following vaccines is Pfizer in 85, Moderna in 46, Oxford/AstraZeneca in 101, and Janssen in 41. JOPSOM 2021; 40(2):65-72
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19疫苗的疗效
随着新型冠状病毒的爆发,科学家和医疗专业人员不知疲倦地开发出一种有效的临床批准疫苗。最初看起来不可能的事情现在已经成为现实,专家们不仅在这么短的时间内制造出了COVID疫苗,而且还开发了不同类型和版本的疫苗。公平获得安全有效的疫苗对于结束COVID- 19大流行至关重要,因此,看到如此多的疫苗得到验证并进入研发阶段是非常令人鼓舞的。世卫组织正在与合作伙伴不懈努力,开发、生产和部署安全有效的疫苗。安全有效的疫苗是改变游戏规则的工具。接种疫苗并不意味着我们可以不顾一切,把自己和他人置于危险之中,特别是因为疫苗不仅可以预防疾病,还可以预防感染和传播的研究仍在进行中。但阻止流感大流行的不是疫苗,而是具有适当效力的疫苗。在100多篇关于COVID-19和SARS-CoV-2疫苗的研究论文中,有41篇被纳入本研究。截至2021年5月1日,全球共发生152 661 445例Covid-19病例,死亡3 202 256例。这次大流行导致人们竞相发现一种安全有效的疫苗,以实现群体免疫,并减少Covid-19的破坏性影响。本研究旨在讨论世卫组织最近批准的Covid-19疫苗亚型及其试验、剂量和功效。截至2021年5月16日,已批准使用以下疫苗的国家为辉瑞85个,Moderna 46个,Oxford/AstraZeneca 101个,杨森41个。JOPSOM 2021;40 (2): 65 - 72
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Association of Serum Prealbumin With Nutritional Status of End-Stage Renal Disease Patients Under Maintenance Hemodialysis Practice of Nurses on Patient Record Management In Tertiary Level Hospitals Nutritional Status and Health Related Quality of Life Of Chronic Kidney Disease Patients Decision Making Empowerment Among Women With And Without Microcredit Coverage Perceived Mental Stress Among Employed And Unemployed Women: A Comparative Cross Sectional Study During COVID-19 Pandemic
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1